Structure Therapeutics prices $650 million public offering

Structure Therapeutics Inc. (NASDAQ: GPCR) announced the pricing of its public offering of American depositary shares and pre-funded warrants, raising approximately $650 million in gross proceeds.

The clinical-stage biopharmaceutical company priced 8,461,538 ADSs at $65.00 per share and 1,538,462 pre-funded warrants at $64.9999 each. Each ADS represents three ordinary shares of the company.

Structure Therapeutics granted underwriters a 30-day option to purchase up to an additional 1,500,000 ADSs at the public offering price, minus underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions.

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are serving as joint book-running managers for the offering. LifeSci Capital and Citizens Capital Markets are acting as co-managers.

The offering is being conducted under an automatic shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on August 6, 2025 and became effective upon filing.

Structure Therapeutics develops oral small molecule therapeutics for metabolic diseases, with a focus on obesity. The company uses a structure-based drug discovery platform to create treatments targeting G-protein-coupled receptors.

You May Also Be Interested In

• KKR to sell 5 million BridgeBio shares in secondary offering
• Dyadic International raises $2.9M via stock offering and warrants
• Hyperscale Data sets 1-for-5 reverse stock split for Aug. 24